and expressed as the mean of a seven point profile obtained over 18 hours before and onec a week during the eight week period. Glycosylated haemo-
globin (HbAL) was measured by a commercial column method (Bio-Rad Laboratories) at the beginning and end of the study.
After dietary treatment the mean glycosylated haemoglobin of the patients fell from 12-1 (SD 38)% to 93 (1.1)% (p<001) (controls 70 (05)%). The mean capillary glucose concentration similarly fell from (0 8) mmol/l to 6-4 (0 4) mmol (p < 0-01). The figure shows the urinary albumin excretion during the same period. At Mean albumin excretion rates before and after exeroise in 10 newly diagnosed non-insulin dependent diabetics before (at diagnosis) and four and eight weeks after the introduction of dietary treatment, and in seven controls (**= p < 0 01). diabetics and the response to exercise statistically highly significant. With dietary treatment (and lowering of capillary glucose concentration and glycosylation index) the response of albuminuria to exercise fell progressively to zero, although the basal excretion rate remained unchanged.
Comment
These observations in non-insulin dependent diabetics suggest that their albumin excretion rate is rather higher at the time of diagnosis than that of controls and that, unlike that of controls, it increases substantially on submaximal exercise. Such a response is pathological, and we must consider seriously the suggestion from studies in insulin dependent diabetics that what starts as a fimctional abnormality of the glomerulus may progress if unchecked to irreversible renal failure.3 Indeed, recent evidence suggests that subclinically abnormal albumin excretion is a strong predictor of mortality in non-insulin dependent diabetes (Viberti et al, British Diabetic Association meeting, Norwich, 1983). Our preliminary experience suggests that dietary treatment alone may be sufficient to reverse the early anomaly.
Our finding that urinary albumin excretion was already abnormal at diagnosis in non-insulin dependent diabetics raises questions about how long glomerular dysfunction may be present before other manifestations of diabetes take the patient to the doctor and whether screening for non-insulin dependent diabetes may prove a fruitful public health prevention measure. Investigations disclosed a normal haemoglobin concentration and erythrocyte sedimentation rate. The leucocyte i;dacount was 6 94X l09/l, with 14% eosinophils (890X 106/1). The myelogram showed considerable expansion of the conus medullaris in both the anteroposterior and lateral views at the level of the first lumbar vertebra (figure), with appearances consistent _ with an intramedullary mass. Cerebrospinal fluid contained protein 0-57 g/l, glucose 0-02 mmol/l (0-34 mg/100 ml) (blood glucose concentration 0 03 mmolfl; 0-62 mg/100 ml), and a white cell count of 66x 109/1 (95% lymphocytes haemoglobin concentration of 10-6 g/dl, which was attributed to her Crohn's colitis, and a blood urea concentration of 8-7 mmol/l (52-3 mg/100 ml).
She was taking digoxin 250 pig daily, frusemide 40 mg daily, and potassium supplements for cardiac failure, with prednisolone enema 20 mg daily and sulphasalazine 2 g daily for Crohn's disease.
In hospital benorylate suspension 5 ml (2 g) four times daily was started for her osteoarthritis. Eight days later she became restless and agitated, and on the following day she became confused and had visual hallucinations.
On examination she was not feverish but was flushed and dehydrated and had considerable tachypnoea. Her haemoglobin concentration was 10-3 g/dl and leucocyte count 4-9X 109/1, and serum concentrations were: urea 18-5 mmol/l (112 mg/100 ml), sodium 144 mmol(mEq)/l, potassium 4-2 mmol (mEq)/l, total carbon dioxide 12 mmol(mEq)/l, chloride 100 mmol(mEq)/l, total protein 73 g/l (7.3g/100 ml), and glucose 4-7 mmol/l (85 mg/100 ml). The pH of her arterial blood was 7-43, oxygen partial pressure 12-9 kPa (97 mm Hg), carbon dioxide partial pressure 2-5 kPa (19 mm Hg), base excess -7-3 mmol (mEq)/l, and standard bicarbonate concentration 18-5 mmol/l. A serum salicylate concentration of 3-06 mmol/l (42-5 mg/100 ml) measured by Trinder's method' confirmed the diagnosis of salicylate intoxication with a compensated metabolic acidosis and increased anion gap. The benorylate and sulphasalazine were stopped and she was given 500 ml lactate 0-16 mol/l intravenously over eight hours followed by isotonic dextrose. Her clinical condition and results of biochemical tests returned to normal within 24 hours.
Sulphasalazine was restarted, and serum salicylate concentrations remained negligible (< 0-12 mmol/l (1-7 mg/100 ml)). Subsequently benorylate suspension was added to her treatment at a dose of 2-5 ml (1 g) four times
daily. The mean of four serum salicylate concentrations obtained before each dose of benorylate after eight days of treatment was 1-85 mmol/l (25-7 mg/100 ml). Serum paracetamol concentrations were less than 0-06 mmol/l (1 mg/100 ml). On the 10th day she developed a mild recurrence of visual hallucinations and confusion, and these again resolved after benorylate was stopped.
OTHER PATIENTS STUDIED
We subsequently studied the effects of benorylate in five female hospital inpatients who yielded normal results to liver function tests. After they had given informed consent they were prescribed benorylate suspension 2-5 ml (1 g) four times daily. The Conversion: SI to traditional units-Urea: 1 mmol/l16 mg/100 ml. Creatinine: 1 ,mol/1u 113 ,g/100 ml. Salicylate: 1 mmol/1 139 mg/100 ml.
Comment
Benorylate was the drug responsible for the salicylate intoxication in the patient described, as administration of sulphasalazine alone did not result in appreciable serum concentrations of salicylate. The five patients studied subsequently achieved a wide range of mean serum salicylate concentrations, which in two cases were as high as in the initial case. This variable response, which has been reported previously,2 did not appear to be related to renal function or body weight. The mean of all serum salicylate concentrations in the five patients studied, who were given 4 g benorylate daily, was 1-25 mmol/l (17 4 mg/100 ml). This is similar to the mean plasma salicylate concentration of 1-26 mmol/l (17-5 mg/100 ml) found in a study of 11 men and 13 women (median age 51) prescribed a mean daily dose of 11-26 g benorylate.3 These findings suggest that the metabolism or excretion, or both, of benorylate occurs at a slower rate in elderly women, although wide individual variation seems to occur.
Benorylate is absorbed unchanged and hydrolysed rapidly to salicylic acid and paracetamol in the intestine and circulation. After further hepatic metabolism it is excreted principally as urinary metabolites of salicylic acid and paracetamol. Hence impaired renal function, common in elderly people, may result in high serum concentrations of salicylate due to reduced excretion.
The administration of more than 4 g benorylate daily in the elderly carries a disproportionately high risk of salicylate intoxication as the serum salicylate concentration is not related to dose.4 In older patients salicylate intoxication may present atypically, diagnosis is often delayed, and mortality is high.5 We conclude that the maximum dose of benorylate in the elderly should be 4 g daily, serum salicylate concentrations should be monitored, and the manufacturer's literature should be amended to state this.
